A cost-utility analysis of interferon beta for multiple sclerosis.

Suppr

超能文献

作者信息

Parkin D, McNamee P, Jacoby A, Miller P, Thomas S, Bates D

机构信息

School of Health Sciences, University of Newcastle-upon-Tyne, UK.

出版信息

Health Technol Assess. 1998;2(4):iii-54.

PMID:9580870

Abstract

摘要

相似文献

A cost-utility analysis of interferon beta for multiple sclerosis.

Health Technol Assess. 1998;2(4):iii-54.

Bad decision NICE.英国国家卫生与临床优化研究所的决定很糟糕。（注：NICE是英国国家卫生与临床优化研究所“National Institute for Health and Care Excellence”的缩写）

Lancet. 2002 Feb 2;359(9304):447. doi: 10.1016/s0140-6736(02)07582-7.

Cost utility of drugs for multiple sclerosis. Systematic review places study in contrast.用于治疗多发性硬化症药物的成本效用。系统评价将该研究置于对比之中。

BMJ. 2000 May 27;320(7247):1474-5; author reply 1475-6.

Cost-effectiveness analysis of interferon beta in multiple sclerosis: a Markov process analysis.干扰素β治疗多发性硬化症的成本效益分析：马尔可夫过程分析

Value Health. 2002 Jan-Feb;5(1):44-54. doi: 10.1046/j.1524-4733.2002.51052.x.

Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.干扰素β-1a、干扰素β-1b和醋酸格拉替雷在新诊断的非原发性进行性多发性硬化症中的成本效益

Value Health. 2004 Sep-Oct;7(5):554-68. doi: 10.1111/j.1524-4733.2004.75007.x.

Treatment of multiple sclerosis with interferon beta: an appraisal of cost-effectiveness and quality of life.用β-干扰素治疗多发性硬化症：成本效益与生活质量评估

J Neurol Neurosurg Psychiatry. 2000 Feb;68(2):144-9. doi: 10.1136/jnnp.68.2.144.

Long-term cost-effectiveness model of interferon beta-1b in the early treatment of multiple sclerosis in the United States.美国多发性硬化症早期采用干扰素β-1b 治疗的长期成本效益模型。

Clin Ther. 2012 Sep;34(9):1966-76. doi: 10.1016/j.clinthera.2012.07.010. Epub 2012 Aug 18.

Interferon beta in multiple sclerosis.多发性硬化症中的β干扰素。

BMJ. 1996 Nov 9;313(7066):1159. doi: 10.1136/bmj.313.7066.1159.

Access denied. While the decision over beta-interferon prescribing hangs in the balance, one thing's for certain--nurses will be left to pick up the pieces.访问被拒绝。虽然关于β-干扰素处方的决定悬而未决，但有一件事是肯定的——护士将不得不收拾残局。

Nurs Stand. 2000;14(44):20. doi: 10.7748/ns.14.44.20.s40.

Cost-effectiveness analysis of interferon beta-1b for the treatment of patients with a first clinical event suggestive of multiple sclerosis.干扰素 β-1b 治疗首次临床提示多发性硬化症患者的成本效益分析。

Clin Ther. 2012 May;34(5):1132-44. doi: 10.1016/j.clinthera.2012.03.004. Epub 2012 Apr 27.

引用本文的文献

Cost-effectiveness Analysis of Ocrelizumab for the Treatment of Relapsing and Primary Progressive Multiple Sclerosis in Portugal.奥瑞珠单抗治疗葡萄牙复发型和原发进展型多发性硬化症的成本效益分析。

Pharmacoecon Open. 2023 Mar;7(2):229-241. doi: 10.1007/s41669-022-00381-z. Epub 2022 Dec 1.

How have Economic Evaluations in Relapsing Multiple Sclerosis Evolved Over Time? A Systematic Literature Review.复发型多发性硬化症的经济学评估如何随时间演变？一项系统文献综述。

Neurol Ther. 2021 Dec;10(2):557-583. doi: 10.1007/s40120-021-00264-1. Epub 2021 Jul 19.

Cost effectiveness analysis of Avonex and CinnoVex in Relapsing Remitting MS.阿沃尼克（Avonex）和西诺维克斯（CinnoVex）用于复发缓解型多发性硬化症的成本效益分析。

Glob J Health Sci. 2014 Oct 9;7(2):139-47. doi: 10.5539/gjhs.v7n2p139.

Cost-utility analysis of disease-modifying drugs in relapsing-remitting multiple sclerosis in Iran.伊朗复发缓解型多发性硬化症疾病修正药物的成本效用分析。

Iran J Neurol. 2012;11(3):87-90.

Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments.不同干扰素 β 产品治疗复发缓解型和继发进展型多发性硬化的成本效益：基于长期临床数据和可转换治疗的决策分析。

Daru. 2013 Jun 22;21(1):50. doi: 10.1186/2008-2231-21-50.

Modelling the cost effectiveness of disease-modifying treatments for multiple sclerosis: issues to consider.模拟多发性硬化症的疾病修正治疗的成本效益：需要考虑的问题。

Pharmacoeconomics. 2013 Jun;31(6):455-69. doi: 10.1007/s40273-013-0063-4.

Cost-effectiveness of multiple sclerosis disease-modifying therapies: a systematic review of the literature.多发性硬化症疾病修正疗法的成本效益：文献系统评价

Autoimmune Dis. 2012;2012:784364. doi: 10.1155/2012/784364. Epub 2012 Dec 6.

Rationing and deprivation: disease-modifying therapies for multiple sclerosis in the United Kingdom.配给和剥夺：英国多发性硬化症的疾病修正治疗。

Eur J Health Econ. 2013 Apr;14(2):315-21. doi: 10.1007/s10198-012-0378-7. Epub 2012 Jan 24.

Assessing cost-effectiveness in the management of multiple sclerosis.评估多发性硬化症管理中的成本效益。

Clinicoecon Outcomes Res. 2009;1:61-78. doi: 10.2147/ceor.s4225. Epub 2009 Nov 18.

Cost-utility analysis: current methodological issues and future perspectives.成本效用分析：当前的方法学问题与未来展望

Front Pharmacol. 2011 Jun 8;2:29. doi: 10.3389/fphar.2011.00029. eCollection 2011.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验